Aelis Farma SA (AELIS.PA)
EUR 1.7
(19.72%)
EUR 1.7
(19.72%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 18.81 Million EUR | 51.23% |
| 2022 | 12.33 Million EUR | 89.04% |
| 2021 | 6.52 Million EUR | 129.8% |
| 2020 | 2.83 Million EUR | -5.08% |
| 2019 | 2.99 Million EUR | 13.68% |
| 2018 | 2.63 Million EUR | 1484.71% |
| 2017 | 166.02 Thousand EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.89 Million EUR | 0.0% |
| 2024 Q1 | 3.89 Million EUR | -27.04% |
| 2023 Q2 | 8.08 Million EUR | 118.39% |
| 2023 FY | 18.65 Million EUR | 51.23% |
| 2023 Q3 | 5.7 Million EUR | -29.42% |
| 2023 Q1 | 3.7 Million EUR | -53.48% |
| 2023 Q4 | 5.33 Million EUR | -6.47% |
| 2022 Q2 | 8.85 Million EUR | 21.64% |
| 2022 Q4 | 7.95 Million EUR | 98.33% |
| 2022 FY | 12.33 Million EUR | 89.04% |
| 2022 Q1 | 7.28 Million EUR | 154.83% |
| 2022 Q3 | 4.01 Million EUR | -54.7% |
| 2021 Q2 | 1.57 Million EUR | 0.0% |
| 2021 Q1 | 1.57 Million EUR | 38.11% |
| 2021 FY | 6.52 Million EUR | 129.8% |
| 2021 Q4 | 2.85 Million EUR | 0.0% |
| 2021 Q3 | 2.85 Million EUR | 81.52% |
| 2020 Q2 | 881 Thousand EUR | 0.0% |
| 2020 Q1 | 881 Thousand EUR | 0.0% |
| 2020 FY | 2.83 Million EUR | -5.08% |
| 2020 Q4 | 1.14 Million EUR | 0.0% |
| 2020 Q3 | 1.14 Million EUR | 29.4% |
| 2019 FY | 2.99 Million EUR | 13.68% |
| 2018 FY | 2.63 Million EUR | 1484.71% |
| 2017 FY | 166.02 Thousand EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -350.539% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 85.226% |
| Adocia SA | 15.62 Million EUR | -20.411% |
| Biophytis S.A. | 14.33 Million EUR | -31.298% |
| Advicenne S.A. | 8.21 Million EUR | -129.081% |
| genOway Société anonyme | 16.73 Million EUR | -12.431% |
| IntegraGen SA | 5.35 Million EUR | -251.592% |
| Medesis Pharma S.A. | 1.56 Million EUR | -1102.821% |
| Neovacs S.A. | 10.34 Million EUR | -81.94% |
| NFL Biosciences SA | 4.37 Million EUR | -330.212% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -580.652% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -995.424% |
| Sensorion SA | 27.05 Million EUR | 30.438% |
| Theranexus Société Anonyme | 3 Million EUR | -526.259% |
| TME Pharma N.V. | 5.49 Million EUR | -242.35% |
| Valbiotis SA | 9.86 Million EUR | -90.688% |
| TheraVet SA | 1.64 Million EUR | -1044.49% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | 7.387% |
| argenx SE | 1.34 Billion EUR | 98.598% |
| BioSenic S.A. | 7.58 Million EUR | -148.174% |
| Celyad Oncology SA | 8.49 Million EUR | -121.661% |
| DBV Technologies S.A. | 89.4 Million EUR | 78.951% |
| Galapagos NV | 327.98 Million EUR | 94.262% |
| Genfit S.A. | 54.8 Million EUR | 65.661% |
| GeNeuro SA | 14.35 Million EUR | -31.076% |
| Hyloris Pharmaceuticals SA | 17.98 Million EUR | -4.626% |
| Innate Pharma S.A. | 64.57 Million EUR | 70.855% |
| Inventiva S.A. | 120.18 Million EUR | 84.342% |
| MaaT Pharma SA | 21.59 Million EUR | 12.867% |
| MedinCell S.A. | 32.92 Million EUR | 42.838% |
| Nanobiotix S.A. | 58.92 Million EUR | 68.064% |
| Onward Medical N.V. | 20.64 Million EUR | 8.845% |
| Oryzon Genomics S.A. | 18.49 Million EUR | -1.74% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | 20.221% |
| Oxurion NV | 12.21 Million EUR | -54.077% |
| Pharming Group N.V. | 204.24 Million EUR | 90.786% |
| Poxel S.A. | 28.76 Million EUR | 34.577% |
| GenSight Biologics S.A. | 32.66 Million EUR | 42.379% |
| Transgene SA | 31.23 Million EUR | 39.743% |
| Financière de Tubize SA | 114.38 Thousand EUR | -16351.757% |
| UCB SA | 2.94 Billion EUR | 99.36% |
| Valneva SE | 134.92 Million EUR | 86.052% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | 23.785% |